Yes, since the beginning of the pandemic, we've been pushing for greater transparency in these licensing agreements. There are a number of reasons behind that.
I'll just jump to the point here and say that we are a medical care provider that is concerned about how vaccines are going to be accessed by our teams as well as by the health systems where we work. We know that there is more demand than there is likely to be supply. The way of closing that gap is likely by having more of these licensing agreements to effectively be able to scale up manufacturing by other quality-assured vaccine manufacturers around the world.
Historically, it's very difficult to know where these licensing agreements have been struck, not just for vaccines and not just for COVID products, but I'm speaking more generally about pharmaceuticals. It becomes very difficult to know what the diversity of manufacturers is going to be and what the supply is going to look like down the line, particularly for new products that are coming on to the market.
Really, our concern here is born out of asking the very basic question, “Is there going to be sufficient supply to meet global demand?” I think that available evidence suggests that the answer is likely to be no. Demand is very high, and supply is quite low.
The second piece, of course, is making sure that these vaccines are going to be affordable.
You mentioned public funding. There's a tremendous amount of public funding, including from the Canadian government, that has gone into supporting the development of these vaccines. We think that that creates a responsibility on the part of pharmaceutical companies to price these affordably, to recognize that the public has paid to develop them.